{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:47:17Z","timestamp":1791229637346,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40257-025-00927-x","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T12:35:21Z","timestamp":1741178121000},"page":"411-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"26","author":[{"given":"Amalie Thorsti M\u00f8ller","family":"R\u00f8nnstad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia-Louise","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Isufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-3280","authenticated-orcid":false,"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"12","key":"927_CR1","doi-asserted-by":"publisher","first-page":"adv00160","DOI":"10.2340\/00015555-3510","volume":"100","author":"S Bylund","year":"2020","unstructured":"Bylund S, von Kobyletzki LB, Svalstedt M, Svensson \u00c5. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"927_CR2","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43-56.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"927_CR3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2013systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"927_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","volume":"75","author":"T Bieber","year":"2020","unstructured":"Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54\u201362.","journal-title":"Allergy"},{"issue":"7","key":"927_CR5","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","volume":"139","author":"LC Tsoi","year":"2019","unstructured":"Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Investig Dermatol. 2019;139(7):1480\u20139.","journal-title":"J Investig Dermatol"},{"issue":"2","key":"927_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/cea.14263","volume":"53","author":"E David","year":"2023","unstructured":"David E, Ungar B, Renert-Yuval Y, Facheris P, Del Duca E, Guttman-Yassky E. The evolving landscape of biologic therapies for atopic dermatitis: present and future perspective. Clin Exp Allergy. 2023;53(2):156\u201372.","journal-title":"Clin Exp Allergy"},{"key":"927_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-54513-9_19","author":"K Lovell","year":"2024","unstructured":"Lovell K, Patel N, Rao S, Strowd LC. The future of atopic dermatitis treatment. Adv Exp Med Biol. 2024. https:\/\/doi.org\/10.1007\/978-3-031-54513-9_19.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"927_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"927_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"AS Halling","year":"2021","unstructured":"Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):139\u201347.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"927_CR10","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh NS, Larsen HHP, Elberling J, Skov L, Ibler KS, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"927_CR11","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/bjd.18031","volume":"181","author":"ZN Willsmore","year":"2019","unstructured":"Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH, et al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. Br J Dermatol. 2019;181(5):1068\u201370.","journal-title":"Br J Dermatol"},{"key":"927_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jdcr.2021.12.011","volume":"21","author":"R Jay","year":"2022","unstructured":"Jay R, Rodger J, Zirwas M. Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management. JAAD Case Rep. 2022;21:14\u20138.","journal-title":"JAAD Case Rep."},{"issue":"6","key":"927_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.21867","volume":"187","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Merola JF, Silverberg JI, Reich K, Warren RB, Staumont-Sall\u00e9 D, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022;187(6):888\u201399.","journal-title":"Br J Dermatol"},{"issue":"3","key":"927_CR14","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.20810","volume":"186","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Beck LA, de Bruin WM, Simpson EL, Imafuku S, Boguniewicz M, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022;186(3):453\u201365.","journal-title":"Br J Dermatol"},{"issue":"5","key":"927_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s13555-022-00721-1","volume":"12","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, Hong HC, Thyssen JP, Calimlim BM, Joshi A, Teixeira HD, et al. Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis. Dermatol Ther (Heidelb). 2022;12(5):1181\u201396.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"5","key":"927_CR16","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/jdv.18881","volume":"37","author":"R Bissonnette","year":"2023","unstructured":"Bissonnette R, Eichenfield LF, Simpson E, Tha\u00e7i D, Kabashima K, Thyssen JP, et al. Estimands for atopic dermatitis clinical trials: expert opinion on the importance of intercurrent events. J Eur Acad Dermatol Venereol. 2023;37(5):976\u201383.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"927_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"issue":"10348","key":"927_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"12","key":"927_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"12","key":"927_CR20","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1080\/14712598.2023.2292627","volume":"23","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Ferrucci SM, Di Nardo L, Gori N, Balato A, Ortoncelli M, et al. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study. Expert Opin Biol Ther. 2023;23(12):1307\u201315.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"927_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jdv.19382","volume":"38","author":"E Pezzolo","year":"2024","unstructured":"Pezzolo E, Schena D, Gambardella A, Rossi M, Barei F, Calzavara Pinton P, et al. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol. 2024;38(1):11\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"927_CR22","doi-asserted-by":"publisher","DOI":"10.25251\/skin.8.supp.318","volume":"8","author":"P Lio","year":"2024","unstructured":"Lio P, Kim Y, Balu S, Costantino H, Bates D, Rene C, et al. Tralokinumab real-world patient-reported outcomes in moderate-to-severe atopic dermatitis adult patients in the United States: 6-month interim analysis. Skin. 2024;8(1): s318.","journal-title":"Skin"},{"key":"927_CR23","unstructured":"NHLBI. Study quality assessment tools. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed 22 Sept 2024."},{"issue":"1","key":"927_CR24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/jvc2.296","volume":"3","author":"F Caroppo","year":"2024","unstructured":"Caroppo F, Belloni FA. Real-life case-series experience with tralokinumab in patients with severe atopic dermatitis. JEADV Clin Pract. 2024;3(1):296\u2013300.","journal-title":"JEADV Clin Pract."},{"issue":"3","key":"927_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/derm.2023.0030","volume":"35","author":"R Garc\u00eda Castro","year":"2024","unstructured":"Garc\u00eda Castro R, Heras Mendaza F, Santiago S\u00e1nchez-Mateos DI, Fari\u00f1a Sabr\u00eds MC, Alcaraz LI. First short-term effectiveness and security data of tralokinumab in severe atopic dermatitis in real clinical practice. Dermatitis. 2024;35(3):301\u20133.","journal-title":"Dermatitis"},{"issue":"1","key":"927_CR26","doi-asserted-by":"publisher","first-page":"2216815","DOI":"10.1080\/09546634.2023.2216815","volume":"34","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Vignoli CA, Facheris P, Valenti M, Costanzo A, et al. Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. J Dermatol Treat. 2023;34(1):2216815.","journal-title":"J Dermatol Treat"},{"issue":"8","key":"927_CR27","doi-asserted-by":"publisher","first-page":"e1064","DOI":"10.1111\/jdv.19108","volume":"37","author":"G Licata","year":"2023","unstructured":"Licata G, Tancredi V, Pezzolo E, Pertusi G, Tolino E, Arisi M, et al. Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: a case series. J Eur Acad Dermatol Venereol. 2023;37(8):e1064\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"927_CR28","doi-asserted-by":"publisher","first-page":"e644","DOI":"10.1111\/jdv.18753","volume":"37","author":"E Pezzolo","year":"2023","unstructured":"Pezzolo E, Naldi L. Tralokinumab in the treatment of resistant atopic dermatitis: an open-label, retrospective case series study. J Eur Acad Dermatol Venereol. 2023;37(5):e644\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"927_CR29","first-page":"e288","volume":"38","author":"A De Greef","year":"2024","unstructured":"De Greef A, Ghislain PD, de Montjoye L, Adriaenssens K, Bulinckx A, Colmant C, et al. Tralokinumab improves clinical scores in adolescents with severe atopic dermatitis: a real-life multicentric observational study. J Eur Acad Dermatol Venereol. 2024;38(3):e288\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"927_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdcr.2024.01.021","volume":"46","author":"EI Herman","year":"2024","unstructured":"Herman EI, Burgy J, Shahriari M. A retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients. JAAD Case Rep. 2024;46:40.","journal-title":"JAAD Case Rep."},{"issue":"1","key":"927_CR31","doi-asserted-by":"publisher","first-page":"2304027","DOI":"10.1080\/09546634.2024.2304027","volume":"35","author":"F Martora","year":"2024","unstructured":"Martora F, Patruno C, D\u2019Ascenzo S, Napolitano M. Injection site reactions after dupilumab or tralokinumab for atopic dermatitis. J Dermatol Treat. 2024;35(1):2304027.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"927_CR32","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/jdv.19643","volume":"38","author":"AH Musters","year":"2024","unstructured":"Musters AH, van Lookeren FL, van der Gang LF, Middelkamp-Hup MA, Bosma AL, Jessurun NT, et al. Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Eur Acad Dermatol Venereol. 2024;38(3):530\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"927_CR33","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.1111\/jdv.19929","volume":"38","author":"N Gori","year":"2024","unstructured":"Gori N, Ippoliti E, Ferrucci SM, Balato A, Ortoncelli M, Maurelli M, et al. Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series. J Eur Acad Dermatol Venereol. 2024;38(10):e852\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"927_CR34","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/bjd\/ljae138","volume":"191","author":"N Sander","year":"2024","unstructured":"Sander N, St\u00f6lzl D, Fonfara M, Hartmann J, Harder I, Suhrkamp I, et al. Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis. Br J Dermatol. 2024;191(3):344\u201350.","journal-title":"Br J Dermatol"},{"issue":"S1","key":"927_CR35","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1089\/derm.2023.0261","volume":"35","author":"L Potestio","year":"2024","unstructured":"Potestio L, Patruno C, Napolitano M. Efficacy and safety of tralokinumab in real life: possible predictive rapid response factors. Dermatitis. 2024;35(S1):S77-80.","journal-title":"Dermatitis"},{"issue":"1","key":"927_CR36","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/jdv.19382","volume":"38","author":"E Pezzolo","year":"2024","unstructured":"Pezzolo E, Schena D, Gambardella A, Rossi M, Barei F, Calzavara Pinton P, et al. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study. J Eur Acad Dermatol Venereol. 2024;38(1):e11\u20133.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"927_CR37","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/ced\/llad038","volume":"48","author":"AR Schl\u00f6sser","year":"2023","unstructured":"Schl\u00f6sser AR, Shareef M, Olydam J, Nijsten TEC, Hijnen DJ. Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clin Exp Dermatol. 2023;48(5):510\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"927_CR38","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/ced\/llad153","volume":"48","author":"JJ Pereyra-Rodr\u00edguez","year":"2023","unstructured":"Pereyra-Rodr\u00edguez JJ, Herranz P, Ruiz-Villaverde R, Elosua-Gonz\u00e1lez M, Gal\u00e1n-Guti\u00e9rrez M, Figueras-Nart I, et al. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results. Clin Exp Dermatol. 2023;48(9):991\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"927_CR39","doi-asserted-by":"publisher","first-page":"2285243","DOI":"10.1080\/09546634.2023.2285243","volume":"34","author":"S Ferrucci","year":"2023","unstructured":"Ferrucci S, Barei F, Tavecchio S, Marzano AV, Zussino M, Naldi L, et al. Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience. J Dermatol Treat. 2023;34(1):2285243.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"927_CR40","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40261-023-01258-7","volume":"43","author":"A De Greef","year":"2023","unstructured":"De Greef A, Ghislain PD, Bulinckx A, Coster A, de Halleux C, Damsin T, et al. Real-life experience of tralokinumab for the treatment of adult patients with severe atopic dermatitis: a multicentric prospective study. Clin Drug Investig. 2023;43(4):299\u2013306.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"927_CR41","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/bjd\/ljae138","volume":"191","author":"N Sander","year":"2024","unstructured":"Sander N, St\u00f6lzl D, Fonfara M, Hartmann J, Harder I, Suhrkamp I, et al. Blockade of interleukin-13 signalling improves skin barrier function and biology in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2024;191(3):344\u201350.","journal-title":"Br J Dermatol"},{"issue":"3","key":"927_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour J, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"3","key":"927_CR43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450\u201363.","journal-title":"Br J Dermatol"},{"issue":"24","key":"927_CR44","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"10086","key":"927_CR45","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"issue":"3","key":"927_CR46","doi-asserted-by":"publisher","first-page":"AB10","DOI":"10.1016\/j.jaad.2024.07.053","volume":"91","author":"R Chovatiya","year":"2024","unstructured":"Chovatiya R, Fakhraie S, Daftary K. 52347: a prospective study of tralokinumab in atopic dermatitis patients with inadequate response to dupilumab. J Am Acad Dermatol. 2024;91(3):AB10.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"927_CR47","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1111\/jdv.20202","volume":"39","author":"G Tavoletti","year":"2025","unstructured":"Tavoletti G, Chiei-Gallo A, Gargiulo L, Avallone G, Ibba L, Barei F, et al. Effectiveness of dupilumab in tralokinumab-resistant patients with atopic dermatitis: a real-world experience from two referral centres. J Eur Acad Dermatol Venereol. 2025;39(2):e163\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"927_CR48","doi-asserted-by":"publisher","first-page":"adv12616","DOI":"10.2340\/actadv.v103.12616","volume":"103","author":"N Loft","year":"2023","unstructured":"Loft N, Egeberg A, Isufi D, Rasmussen MK, Bryld LE, Ajgeiy KK, et al. Response to interleukin-17A inhibitors according to prior biologic exposures: a Danish nationwide study. Acta Derm Venereol. 2023;103:adv12616.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"927_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jaad.2020.07.085","volume":"84","author":"N Loft","year":"2021","unstructured":"Loft N, Halling AS, Egeberg A, Skov L. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(1):130\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"927_CR50","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","volume":"152","author":"AWL Chu","year":"2023","unstructured":"Chu AWL, Wong MM, Rayner DG, Guyatt GH, Martinez JPD, Ceccacci R, et al. Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1470\u201392.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"927_CR51","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon S, Kim K, Shin K, Kim H, Kim B, Kim M, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2024;38(1):52\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"927_CR52","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459\u201373.","journal-title":"Br J Dermatol"},{"issue":"5","key":"927_CR53","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/bjd.17538","volume":"180","author":"DS Bakker","year":"2019","unstructured":"Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol. 2019;180(5):1248\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"927_CR54","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1111\/jdv.15914","volume":"34","author":"AN Voorberg","year":"2020","unstructured":"Voorberg AN, den Dunnen WFA, Wijdh RHJ, de Bruin-Weller MS, Schuttelaar MLA. Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis. J Eur Acad Dermatol Venereol. 2020;34(2):e64\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"927_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12835","volume":"91","author":"P Br\u00f8gger","year":"2020","unstructured":"Br\u00f8gger P, Blom LH, Simonsen S, Thyssen JP, Skov L. Antagonism of the interleukin 4 receptor \u03b1 promotes TH1-signalling among T cells from patients with atopic dermatitis after stimulation. Scand J Immunol. 2020;91(1): e12835.","journal-title":"Scand J Immunol"},{"key":"927_CR56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtos.2020.05.008","volume":"19","author":"CA Utine","year":"2021","unstructured":"Utine CA, Li G, Asbell P, Pflugfelder S, Akpek E. Ocular surface disease associated with dupilumab treatment for atopic diseases. Ocul Surf. 2021;19:151\u20136.","journal-title":"Ocul Surf"},{"issue":"5","key":"927_CR57","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1111\/bjd.16330","volume":"178","author":"JP Thyssen","year":"2018","unstructured":"Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol. 2018;178(5):1220.","journal-title":"Br J Dermatol"},{"issue":"3","key":"927_CR58","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaad.2021.05.013","volume":"86","author":"CM Brumfiel","year":"2022","unstructured":"Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. J Am Acad Dermatol. 2022;86(3):708\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"927_CR59","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339\u201347.","journal-title":"J Am Acad Dermatol"},{"key":"927_CR60","volume-title":"AB0573 dupilumab-induced enthesitis\/arthritis in patients with atopic dermatitis: a retrospective observational study","author":"J Nathan","year":"2021","unstructured":"Nathan J, Hughes C, Patel S, Mathew L, Smith C, Pink A, et al. AB0573 dupilumab-induced enthesitis\/arthritis in patients with atopic dermatitis: a retrospective observational study. London: BMJ Publishing Group Ltd; 2021."},{"issue":"7","key":"927_CR61","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/1346-8138.16764","volume":"50","author":"M Napolitano","year":"2023","unstructured":"Napolitano M, Fabbrocini G, Patruno C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study. J Dermatol. 2023;50(7):880\u20137.","journal-title":"J Dermatol"}],"updated-by":[{"DOI":"10.1007\/s40257-025-00948-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00927-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T05:03:08Z","timestamp":1747458188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00927-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-025-00948-6","URL":"https:\/\/doi.org\/10.1007\/s40257-025-00948-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Amalie Thorsti M\u00f8ller R\u00f8nnstad has received research funding from the Department of Clinical Medicine, Copenhagen University and the Kgl Hofbundtmager Aage Bang Foundation. Masahiro Kamata received honoraria for lectures from LEO Pharma, AbbVie, Eli Lilly, Janssen, UCB, Boehringer Ingelheim, Bristol Myers Squibb, Kyowa Kirin, Torii, Taiho and Maruho. Mia-Louise Nielsen has received consultancy honoraria from LEO Pharma. Simon F. Thomsen has received research support from Janssen, LEO Pharma, Novartis, Sanofi and UCB, and has been a speaker\/consultant for AbbVie, CSL, Eli Lilly, Janssen, Galderma, Incyte, LEO Pharma, Novartis, Pfizer, Sanofi, Symphogen, UCB and Union Therapeutics. Christian Vestergaard has been an investigator for AbbVie A\/S, Pierre Fabre Dermo-Cosmetique, Novartis, LEO Pharma, Sanofi, Almirall, Galderma and Pfizer. He has served on advisory boards for Astellas Pharma, Almirall, Sanofi, Abb-Vie, Galderma, Leo Pharma and MEDA, and has been a speaker for Leo-Pharma, Astellas, MSD, AbbVie, Novartis Almirall, Sanofi and Pfizer. Raj Chovatiya served as an advisor, consultant, speaker and\/or investigator for AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRexBio and UCB. Christopher G. Bunick has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Timber and Palvella, a consultant for AbbVie, Almirall, Apogee, Arcutis, Connect BioPharma, Eli Lilly, EPI Health\/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, Takeda and UCB, and a speaker for and received honoraria from Allergan, Almirall, LEO Pharma, and UCB. Andreas Wollenberg has served as an advisor or paid speaker for, or participated in clinical trials (with honoraria paid to the institution) sponsored by AbbVie, Aileens, Almirall, Amgen, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, DKSH, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Janssen-Cilag, Kyowa Kirin, Leo Pharma, L\u2019Oreal, Maruho, MedImmune, MSD, Mylan, MSD, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi-Aventis and UCB. Alexander Egeberg has received research funding from Almirall, Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, Boehringer Ingelheim, the Danish National Psoriasis Foundation, the Simon Spies Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as a consultant and\/or speaker from Amgen, AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Gal\u00e1pagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim and Janssen Pharmaceuticals. He is currently an employee at LEO Pharma. Jacob P. Thyssen has been an advisor for AbbVie, Almirall, Arena Pharmaceuticals, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron and Sanofi-Genzyme. He is currently an employee at LEO Pharma. Nikolai Loft has been a paid speaker for Eli Lilly, Janssen Cilag and Sandoz, and received research funding from the LEO Foundation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data and material are available upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code is available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"NL, DI, ATMR and M-LN had full access to all the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: NL, CGB, RC, JPT and AE. Acquisition, analysis and interpretation of data: all authors. Drafting of the manuscript: NL and ATMR. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: M-LN. Administrative, technical or material support: none. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}